Statera Biopharma Stock Gross Profit

STABDelisted Stock  USD 0.04  0.0003  0.82%   
Statera Biopharma fundamentals help investors to digest information that contributes to Statera Biopharma's financial success or failures. It also enables traders to predict the movement of Statera Pink Sheet. The fundamental analysis module provides a way to measure Statera Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Statera Biopharma pink sheet.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Statera Biopharma Company Gross Profit Analysis

Statera Biopharma's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Gross Profit

 = 

Revenue

-

Cost of Revenue

More About Gross Profit | All Equity Analysis

Current Statera Biopharma Gross Profit

    
  998.72 K  
Most of Statera Biopharma's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Statera Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
Competition

According to the company disclosure, Statera Biopharma reported 998.72 K of gross profit. This is 99.96% lower than that of the Healthcare sector and 99.89% lower than that of the Biotechnology industry. The gross profit for all United States stocks is 100.0% higher than that of the company.

Statera Gross Profit Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Statera Biopharma's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Statera Biopharma could also be used in its relative valuation, which is a method of valuing Statera Biopharma by comparing valuation metrics of similar companies.
Statera Biopharma is currently under evaluation in gross profit category among its peers.

Statera Fundamentals

About Statera Biopharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Statera Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Statera Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Statera Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Other Consideration for investing in Statera Pink Sheet

If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Commodity Directory
Find actively traded commodities issued by global exchanges
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges